Drug Trial Radar · NCT03008083
Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation
Last checked: Nov 19, 2026Latest source record: Sep 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,446
Planned (sponsor's estimate)
Start
Jan 10, 2019
Primary completion
Dec 2020
Study completion Oct 2022
Sponsor
- Lead sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective,multi-center, open-label, randomized controlled clinical trial,aims to assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in patients undergoing percutaneous coronary intervention implanted sirolimus target- eluting stent with abluminal grooves containing a biodegradable polymer (Firehawk™ stent). All participants met the inclusion criteria begin taking aspirin and open-label thienopyridine therapy before index procedure, and will be 1:1 randomized to 3 months or 12 month of DAPT at index procedure.
Conditions
- Drug-Eluting Stents
- Percutaneous Coronary Intervention
Interventions
3 months DAPTDrug
Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
12 months DAPTDrug
Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Net Adverse Clinical and Cerebral Events (NACCE)Time frame: At 18 months after index procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Zhongshan Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.